Anke Henning

Anke Henning

Auto-generated profile, based on publicly available information

Anke Henning

University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Radiology
Verified
Journal Article
Closed access
GOGulin Oz
Gulin Oz
JAJeffry R. Alger
Jeffry R. Alger
PBPeter B. Barker
Peter B. Barker
RBRobert Bartha
Robert Bartha
ABAlberto Bizzi
Alberto Bizzi
FGFor the MRS Consensus Group
For the MRS Consensus Group
MR spectroscopy is used worldwide as an adjunct to MR imaging in several common neurologic diseases, including brain neoplasms, inherited metabolic disorders, demyelinating disorders, and infective... A large body of published work shows that proton (hydrogen 1 [1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors p...

23 September 2005 in Science
Verified
Journal Article
Closed access
PDF file
FOFlorian C. Oberstrass
Florian C. Oberstrass
SASigrid D. Auweter
Sigrid D. Auweter
MEMichèle Erat
Michèle Erat
YHYann Hargous
Yann Hargous
AHAnke Henning
Anke Henning
FAFrederic Allain
Frederic Allain
The polypyrimidine tract binding protein (PTB) is a 58-kilodalton RNA binding protein involved in multiple aspects of messenger RNA metabolism, including the repression of alternative exons. We have determined the solution structures of the four RNA binding domains (RBDs) of PTB, each bound to a CUCUCU oligonucleotide. Each RBD binds RNA with a different binding specificity. RBD3 and RBD4 interact, resulting in an antiparallel orientation of their bound RNAs. Thus, PTB will induce RNA looping when bound to two separated pyrimidine tracts within the same RNA. This leads to structural models for how PTB functions as an alternative-splicing repressor.

4 November 2007 in Nature Neuroscience
Verified
Journal Article
Closed access
GNGeorg Northoff
Georg Northoff
MWMartin Walter
Martin Walter
RSRolf F Schulte
Rolf F Schulte
JBJohannes Beck
Johannes Beck
UDUlrike Dydak
Ulrike Dydak
PBPeter Boesiger
Peter Boesiger

1 July 2009 in JACC
Verified
Journal Article
Closed access
TPThanh T. Phan
Thanh T. Phan
KAKhalid Abozguia
Khalid Abozguia
GSGanesh Nallur Shivu
Ganesh Nallur Shivu
GMGnanadevan Mahadevan
Gnanadevan Mahadevan
IAIbrar Ahmed
Ibrar Ahmed
MFMichael Frenneaux
Michael Frenneaux

19 October 2010 in Circulation
Verified
Journal Article
Closed access
KAKhalid Abozguia
Khalid Abozguia
Perry ElliottPerry Elliott
Perry Elliott
WMWilliam McKenna
William McKenna
TPThanh Trung Phan
Thanh Trung Phan
GNGanesh Nallur-Shivu
Ganesh Nallur-Shivu
MFMichael Frenneaux
Michael Frenneaux
Background—: Hypertrophic cardiomyopathy patients exhibit myocardial energetic impairment, but a causative role for this energy deficiency in the pathophysiology of hypertrophic cardiomyopathy remains unproven. We hypothesized that the metabolic modulator perhexiline would ameliorate myocardial energy deficiency and thereby improve diastolic function and exercise capacity. Methods and Results—: Forty-six consecutive patients with symptomatic exercise limitation (peak V̇ o 2 <75% of predicted) caused by nonobstructive hypertrophic cardiomyopathy (mean age, 55±0.26 years) were randomized to perhexiline 100 mg (n=24) or placebo (n=22). Myocardial ratio of phosphocreatine to adenosine triphosphate, an established marker of cardiac energetic status, as measured by 31 P magnetic resonance spectroscopy, left ventricular diastolic filling (heart rate normalized time to peak filling) at rest and during exercise using radionuclide ventriculography, peak V̇o 2 , symptoms, quality of life, and serum metabolites were assessed at baseline and study end (4.6±1.8 months). Perhexiline improved myocardial ratios of phosphocreatine to adenosine triphosphate (from 1.27±0.02 to 1.73±0.02 versus 1.29±0.01 to 1.23±0.01; P =0.003) and normalized the abnormal prolongation of heart rate normalized time to peak filling between rest and exercise (0.11±0.008 to −0.01±0.005 versus 0.15±0.007 to 0.11±0.008 second; P =0.03). These changes were accompanied by an improvement in primary end point (peak V̇ o 2 ) (22.2±0.2 to 24.3±0.2 versus 23.6±0.3 to 22.3±0.2 mL · kg −1 · min −1 ; P =0.003) and New York Heart Association class ( P <0.001) (all P values ANCOVA, perhexiline versus placebo). Conclusions—: In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00500552.

1 May 2009 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MWMartin Walter
Martin Walter
AHAnke Henning
Anke Henning
SGSimone Grimm
Simone Grimm
RSRolf F. Schulte
Rolf F. Schulte
JBJohannes Beck
Johannes Beck
GNGeorg Northoff
Georg Northoff
Recent studies on major depressive disorder (MDD) revealed altered brain responses during functional magnetic resonance imaging (fMRI) in the medial prefrontal cortex and the pregenual anterior cingulate cortex (pgACC),1-3 a region specifically relevant for expression of anhedonic behavior in depression.2 Findings comprised abnormal corticothalamic connectivity4 and metabolism5,6 at rest and altered blood oxygenation level–dependent (BOLD) signal changes during different emotional/cognitive tasks.7,8 The pgACC is part of the default mode network and thus characterized by negative BOLD responses (NBRs) on emotional stimulation.9,10 Previously functional abnormalities, such as decreased NBRs, were reported in the pgACC of patients with MDD.11